Comparison of Cryoballoon Ablation Methods in Pulmonary Vein Isolation
- PMID: 41303757
- PMCID: PMC12654706
- DOI: 10.3390/medicina61111920
Comparison of Cryoballoon Ablation Methods in Pulmonary Vein Isolation
Abstract
Background and Objectives: Cryoballoon ablation is a well-established therapy for atrial fibrillation (AF), enabling pulmonary vein isolation (PVI) using a single-shot technique. The two primary systems-Medtronic Arctic Front and the newer Boston Scientific POLARx-differ in design and performance characteristics, but few direct comparisons exist. This study aimed to compare the biophysical parameters and mid-term outcomes of the POLARx and Arctic Front cryoballoon systems. Materials and Methods: In a retrospective analysis of 200 patients who underwent cryoballoon ablation for paroxysmal or persistent AF, patients were grouped by ablation system: POLARx (n = 107) and Arctic Front (n = 93). Key parameters including nadir balloon temperatures, time to reach -40 °C, procedure duration, dose area product (DAP), complication rates, and recurrence of AF were assessed. Results: The POLARx system achieved significantly lower nadir temperatures in all pulmonary veins compared to Arctic Front (left superior PV: -57.6 ± 5.0 °C vs. -50.1 ± 5.7 °C, p < 0.001). Time to reach -40 °C was also shorter with POLARx (left superior PV: 23.3 ± 7.3 s vs. 33.3 ± 11.5 s, p < 0.001). Despite these advantages, procedure time was longer in the POLARx group (64.7 ± 14.8 min vs. 51.6 ± 19.7 min, p < 0.001). AF recurrence at 11.8 months was similar (33.6% in POLARx vs. 39.8% in Arctic Front, p = 0.93). Phrenic nerve palsy occurred in 5.0% (POLARx) and 4.3% (Arctic Front), with no cases of cardiac tamponade. Conclusions: While both systems demonstrated similar efficacy and safety, POLARx was associated with superior cooling kinetics and biophysical performance.
Keywords: atrial fibrillation; cryoballoon ablation; pulmonary vein isolation.
Conflict of interest statement
The authors declare no conflicts of interest.
Figures
References
-
- Van Gelder I.C., Rienstra M., Bunting K.V., Casado-Arroyo R., Caso V., Crijns H.J.G.M., De Potter T.J.R., Dwight J., Guasti L., Hanke T., et al. 2024 ESC Guidelines for the Management of Atrial Fibrillation Developed in Collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): Developed by the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC), with the Special Contribution of the European Heart Rhythm Association (EHRA) of the ESC. Endorsed by the European Stroke Organisation (ESO) Eur. Heart J. 2024;45:3314–3414. doi: 10.1093/eurheartj/ehae176. - DOI - PubMed
-
- Hindricks G., Potpara T., Dagres N., Arbelo E., Bax J.J., Blomström-Lundqvist C., Boriani G., Castella M., Dan G.-A., Dilaveris P.E., et al. 2020 ESC Guidelines for the Diagnosis and Management of Atrial Fibrillation Developed in Collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the Diagnosis and Management of Atrial Fibrillation of the European Society of Cardiology (ESC) Developed with the Special Contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur. Heart J. 2021;42:373–498. doi: 10.1093/eurheartj/ehaa612. - DOI - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
